Journal
CANCER IMMUNOLOGY IMMUNOTHERAPY
Volume 69, Issue 2, Pages 237-244Publisher
SPRINGER
DOI: 10.1007/s00262-019-02421-w
Keywords
TAM receptors; MERTK; PROS1; T lymphocytes; Costimulation; CITIM 2019
Categories
Funding
- Training Network for the Immunotherapy of Cancer (IMMUTRAIN, H2020) - European Union [641549]
- Marie Curie Actions (MSCA) [641549] Funding Source: Marie Curie Actions (MSCA)
Ask authors/readers for more resources
The TAM receptors-TYRO3, AXL, MERTK-are pleiotropically expressed receptors in both healthy and diseased tissue. A complex of the ligands Protein S (PROS1) or Growth Arrest-Specific 6 (GAS6) with apoptotic phosphatidylserine activates the TAM receptors. Hence, this receptor family is essential for the efferocytosis of apoptotic material by antigen-presenting cells. In addition, TAM receptors are expressed by virtually all cells of the tumor microenvironment. They are also potent oncogenes, frequently overexpressed in cancer and involved in survival and therapy resistance. Due to their pro-oncogenic and immune-inhibitory traits, TAM receptors have emerged as promising targets for cancer therapy. Recently, TAM receptors have been described to function as costimulatory molecules on human T cells. TAM receptors' ambivalent functions on many different cell types therefore make therapeutic targeting not straight-forward. In this review we summarize our current knowledge of the function of TAM receptors in the tumor microenvironment. We place particular focus on TAM receptors and the recently unraveled role of MERTK in activated T cells and potential consequences for anti-tumor immunity.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available